Discovery, Development and Application of Innovative Approaches to Cancer Therapy
Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 4022
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; immune resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals
Immune checkpoint inhibitors (ICIs) are at the forefront in systemic therapy for various types of advanced cancer with impressive results. However, only a minority of cancer patients have benefited from this type of immunotherapy and several ICI clinical trials have failed to produce long-term clinical benefits. Therapeutic cancer vaccines have also failed to generate clinically significant outcomes in large phase III trials. The lack of robust clinically results, despite the ability of immunotherapies to prime and expand tumor antigen-specific T-cells, could at least be partially attributed to the inability of immunotherapy-induced T-cell antitumor responses to overcome immune escape mechanisms developed by the tumors. Such mechanisms attenuate the functional program and also limit the clonal expansion of tumor-reactive T-cells following the application of immunotherapies. Strategies aimed at modulating the evasion of tumors from immune surveillance have shown promising results that reform the therapeutic landscape of cancer. This Special Issue aims to focus on the discovery, development, and application of novel cellular and molecular approaches, applied as single therapeutic modalities or in combination, for the prevention and treatment of cancer. To this end, this Special Issue will accept manuscripts addressing translational cancer research, clinical research, and clinical studies on various topics including, but not limited to, immune checkpoint inhibitors , chimeric antigen receptor (CAR) T/NK-cell therapy and other cell therapies, vaccine-based therapies, combinatorial therapies, prognostic/predictive biomarkers, resistance mechanisms, microbiome and Immunotherapies, as well as novel targets of immunotherapies in the tumor microenvironment and in the periphery and management of therapy-induced toxicities.
Dr. Constantin N. Baxevanis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint inhibitors
- cell therapies
- CAR T/NK cells
- immune resistance
- immune surveillance
- targeted therapies
- combinational therapeutic strategies